Order Article Reprints

Passeri T, Dahmani A, Masliah-Planchon J, Naguez A, Michou M, El Botty R, Vacher S, Bouarich R, Nicolas A, Polivka M, et al. Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. Cancers. 2022; 14(6):1486. https://doi.org/10.3390/cancers14061486

Passeri, Thibault, Ahmed Dahmani, Julien Masliah-Planchon, Adnan Naguez, Marine Michou, Rania El Botty, Sophie Vacher, Rachida Bouarich, André Nicolas, Marc Polivka, and et al. 2022. "Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft" Cancers 14, no. 6: 1486. https://doi.org/10.3390/cancers14061486

Passeri, T., Dahmani, A., Masliah-Planchon, J., Naguez, A., Michou, M., El Botty, R., Vacher, S., Bouarich, R., Nicolas, A., Polivka, M., Franck, C., Schnitzler, A., Némati, F., Roman-Roman, S., Bourdeaut, F., Adle-Biassette, H., Mammar, H., Froelich, S., Bièche, I., & Decaudin, D. (2022). Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. Cancers, 14(6), 1486. https://doi.org/10.3390/cancers14061486